Date: 2016-11-10
Type of information: Capital increase
Company: Transgene (France)
Investors: Institut Mérieux (France)
Amount: €46.4 million
Funding type: capital increase
Planned used: Transgene intends to use the net proceeds from the offering to reinforce its financial structure until the end of 2018 in order to carry out its clinical development plan with the launch of seven clinical trials currently under preparation, evaluating its five clinical-stage drug candidate products. and (ii) allow the Company to negotiate partnership agreements based on the results obtained from 2017 onwards.
Others: * On November 10, 2016, Transgene announced the successful completion of its share capital increase with shareholders' preferential subscription rights which was launched on October 20, 2016. Total gross proceeds of the Rights Issue amount to €46,407,514.40, issuance premium included, corresponding to the issuance of 17,849,044 new shares at a subscription price of €2.60 per share, corresponding to a subscription rate of approx. 96.5%.
- 13,152,948 new shares were subscribed for by irrevocable entitlement ("à titre irréductible"), representing 73.69% of the new shares to be issued;
- Subscriptions subject to reduction ("à titre réductible") amounted to 4,696,096 new shares, representing 26.31% of the new shares to be issued, and will, as a result, be fully satisfied.
The Institut Mérieux subscription, through its subsidiary TSGH, comprises 9,593,772 new shares subscribed for by irrevocable entitlement ("à titre irréductible") and 4,282,575 new shares subject to reduction ("à titre réductible"), which will be fully allocated. After completion of the Rights Issue, the company's share capital will amount to €56,394,441, divided into 56,394,441 shares with a par value of €1.00. TSGH will hold 60% of Transgene share capital and 69.1% of the voting rights.Natixis acted as Global Coordinator and Joint Bookrunner and Kempen & Co acted as Joint Bookrunner for the Rights Issue.
Therapeutic area: Cancer - Oncology - Infectious diseases
